The DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.
The CD47‐SIRPα signaling axis as an innate immune checkpoint in cancer
Open accessAbstract
Summary: Immune checkpoint inhibitors, including those targeting CTLA‐4/B7 and the PD‐1/PD‐L1 inhibitory pathways, are now available for clinical use in cancer patients, with other interesting checkpoint inhibitors being currently in development. Most of these have the purpose to promote adaptive T cell‐mediated immunity against cancer. Here, we review another checkpoint acting to potentiate the activity of innate immune cells towards cancer. This innate immune checkpoint is composed of what has become known as the ‘don't‐eat me’ signal CD 47, which is a protein broadly expressed on normal cells and often overexpressed on cancer cells, and its counter‐receptor, the myeloid inhibitory immunoreceptor SIRP α. Blocking CD 47‐SIRP α interactions has been shown to promote the destruction of cancer cells by phagocytes, including macrophages and neutrophils. Furthermore, there is growing evidence that targeting of the CD 47‐SIRP α axis may also promote antigen‐presenting cell function and thereby stimulate adaptive T cell‐mediated anti‐cancer immunity. The development of CD 47‐SIRP α checkpoint inhibitors and the potential side effects that these may have are discussed. Collectively, this identifies the CD 47‐SIRP α axis as a promising innate immune checkpoint in cancer, and with data of the first clinical studies with CD 47‐SIRP α checkpoint inhibitors expected within the coming years, this is an exciting and rapidly developing field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
Weber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676
Couzin-Frankel, J. (2013) · Science · doi:10.1126/science.342.6165.1432 · Cited by 2,051
Role of CD47 as a Marker of Self on Red Blood Cells
Oldenborg, P.-A., Zheleznyak, A., Fang, Y.-F., Lagenaur, C. F., Gresham, H. D., & Lindberg, F. P. (2000) · Science · doi:10.1126/science.288.5473.2051 · Cited by 1,970
Majeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.045 · Cited by 1,752
Willingham, S. B., Volkmer, J.-P., Gentles, A. J., Sahoo, D., Dalerba, P., Mitra, S. S., Wang, J., Contreras-Trujillo, H., Martin, R., Cohen, J. D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121623109 · Cited by 1,666
CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Jaiswal, S., Jamieson, C. H. M., Pang, W. W., Park, C. Y., Chao, M. P., Majeti, R., Traver, D., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.046 · Cited by 1,581
Bruhns, P., Iannascoli, B., England, P., Mancardi, D. A., Fernandez, N., Jorieux, S., & Daëron, M. (2009) · Blood · doi:10.1182/blood-2008-09-179754 · Cited by 1,479
Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70054-9 · Cited by 1,415
MYC regulates the antitumor immune response through CD47 and PD-L1
Casey, S. C., Tong, L., Li, Y., Do, R., Walz, S., Fitzgerald, K. N., Gouw, A. M., Baylot, V., Gütgemann, I., Eilers, M., et al. (2016) · Science · doi:10.1126/science.aac9935 · Cited by 1,403
McMillan, D. C. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.08.003 · Cited by 1,398
Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70122-1 · Cited by 1,262
Chao, M. P., Alizadeh, A. A., Tang, C., Myklebust, J. H., Varghese, B., Gill, S., Jan, M., Cha, A. C., Chan, C. K., Tan, B. T., et al. (2010) · Cell · doi:10.1016/j.cell.2010.07.044 · Cited by 1,087
Engineered T cells: the promise and challenges of cancer immunotherapy
Fesnak, A. D., June, C. H., & Levine, B. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.97 · Cited by 1,074
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981
Integrin-associated protein (CD47) and its ligands
Brown, E. (2001) · Trends in Cell Biology · doi:10.1016/s0962-8924(00)01906-1 · Cited by 878
Barclay, A. N., & van den Berg, T. K. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120142 · Cited by 841
Chao, M. P., Jaiswal, S., Weissman-Tsukamoto, R., Alizadeh, A. A., Gentles, A. J., Volkmer, J., Weiskopf, K., Willingham, S. B., Raveh, T., Park, C. Y., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001375 · Cited by 776
CD47 blockade triggers T cell–mediated destruction of immunogenic tumors
Liu, X., Pu, Y., Cron, K., Deng, L., Kline, J., Frazier, W. A., Xu, H., Peng, H., Fu, Y.-X., & Xu, M. M. (2015) · Nature Medicine · doi:10.1038/nm.3931 · Cited by 767
CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis
Kojima, Y., Volkmer, J.-P., McKenna, K., Civelek, M., Lusis, A. J., Miller, C. L., Direnzo, D., Nanda, V., Ye, J., Connolly, A. J., et al. (2016) · Nature · doi:10.1038/nature18935 · Cited by 683
Chan, K. S., Espinosa, I., Chao, M., Wong, D., Ailles, L., Diehn, M., Gill, H., Presti, J., Chang, H. Y., van de Rijn, M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906549106 · Cited by 660
Tseng, D., Volkmer, J.-P., Willingham, S. B., Contreras-Trujillo, H., Fathman, J. W., Fernhoff, N. B., Seita, J., Inlay, M. A., Weiskopf, K., Miyanishi, M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305569110 · Cited by 657
Decreased Resistance to Bacterial Infection and Granulocyte Defects in IAP-Deficient Mice
Lindberg, F. P., Bullard, D. C., Caver, T. E., Gresham, H. D., Beaudet, A. L., & Brown, E. J. (1996) · Science · doi:10.1126/science.274.5288.795 · Cited by 607
Mouse and human FcR effector functions
Bruhns, P., & Jönsson, F. (2015) · Immunological Reviews · doi:10.1111/imr.12350 · Cited by 579
Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells
Takenaka, K., Prasolava, T. K., Wang, J. C. Y., Mortin-Toth, S. M., Khalouei, S., Gan, O. I., Dick, J. E., & Danska, J. S. (2007) · Nature Immunology · doi:10.1038/ni1527 · Cited by 509
Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies
Weiskopf, K., Ring, A. M., Ho, C. C. M., Volkmer, J.-P., Levin, A. M., Volkmer, A. K., Özkan, E., Fernhoff, N. B., van de Rijn, M., Weissman, I. L., et al. (2013) · Science · doi:10.1126/science.1238856 · Cited by 495
Tsai, R. K., & Discher, D. E. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200708043 · Cited by 486
Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential
Liu, J., Wang, L., Zhao, F., Tseng, S., Narayanan, C., Shura, L., Willingham, S., Howard, M., Prohaska, S., Volkmer, J., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0137345 · Cited by 475
Cd47-Signal Regulatory Protein α (Sirpα) Regulates Fcγ and Complement Receptor–Mediated Phagocytosis
Oldenborg, P.-A., Gresham, H. D., & Lindberg, F. P. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.7.855 · Cited by 452
Zhang, H., Lu, H., Xiang, L., Bullen, J. W., Zhang, C., Samanta, D., Gilkes, D. M., He, J., & Semenza, G. L. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520032112 · Cited by 420
FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis
Dahan, R., Sega, E., Engelhardt, J., Selby, M., Korman, A. J., & Ravetch, J. V. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.08.004 · Cited by 409
Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia
Chao, M. P., Alizadeh, A. A., Tang, C., Jan, M., Weissman-Tsukamoto, R., Zhao, F., Park, C. Y., Weissman, I. L., & Majeti, R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2238 · Cited by 382
SHP‐1 and SHP‐2 in T cells: two phosphatases functioning at many levels
Lorenz, U. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00760.x · Cited by 372
Durable antitumor responses to CD47 blockade require adaptive immune stimulation
Sockolosky, J. T., Dougan, M., Ingram, J. R., Ho, C. C. M., Kauke, M. J., Almo, S. C., Ploegh, H. L., & Garcia, K. C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1604268113 · Cited by 366
Integrin-associated Protein Is a Ligand for the P84 Neural Adhesion Molecule
Jiang, P., Lagenaur, C. F., & Narayanan, V. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.2.559 · Cited by 351
Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model
Hu, Y., Turner, M. J., Shields, J., Gale, M. S., Hutto, E., Roberts, B. L., Siders, W. M., & Kaplan, J. M. (2009) · Immunology · doi:10.1111/j.1365-2567.2009.03115.x · Cited by 335
Zhang, M., Hutter, G., Kahn, S. A., Azad, T. D., Gholamin, S., Xu, C. Y., Liu, J., Achrol, A. S., Richard, C., Sommerkamp, P., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0153550 · Cited by 330
Fc receptors are required in passive and active immunity to melanoma
Clynes, R., Takechi, Y., Moroi, Y., Houghton, A., & Ravetch, J. V. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.2.652 · Cited by 321
POSITIVE VERSUS NEGATIVE SIGNALING BY LYMPHOCYTE ANTIGEN RECEPTORS
Healy, J. I., & Goodnow, C. C. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.645 · Cited by 316
Role for CD47-SIRPα signaling in xenograft rejection by macrophages
Ide, K., Wang, H., Tahara, H., Liu, J., Wang, X., Asahara, T., Sykes, M., Yang, Y.-G., & Ohdan, H. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609661104 · Cited by 304
Seiffert, M., Cant, C., Chen, Z., Rappold, I., Brugger, W., Kanz, L., Brown, E. J., Ullrich, A., & Bühring, H.-J. (1999) · Blood · doi:10.1182/blood.v94.11.3633 · Cited by 303
Negative Regulation of Phagocytosis in Macrophages by the CD47-SHPS-1 System
Okazawa, H., Motegi, S.-I., Ohyama, N., Ohnishi, H., Tomizawa, T., Kaneko, Y., Oldenborg, P.-A., Ishikawa, O., & Matozaki, T. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.4.2004 · Cited by 302
Isenberg, J. S., Ridnour, L. A., Dimitry, J., Frazier, W. A., Wink, D. A., & Roberts, D. D. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605040200 · Cited by 289
Kimura, H., Sakai, K., Arao, T., Shimoyama, T., Tamura, T., & Nishio, K. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00510.x · Cited by 277
Zhao, X. W., van Beek, E. M., Schornagel, K., Van der Maaden, H., Van Houdt, M., Otten, M. A., Finetti, P., Van Egmond, M., Matozaki, T., Kraal, G., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106550108 · Cited by 276
Self-citationDifferential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect
DiLillo, D. J., & Ravetch, J. V. (2015) · Cell · doi:10.1016/j.cell.2015.04.016 · Cited by 266
Edris, B., Weiskopf, K., Volkmer, A. K., Volkmer, J.-P., Willingham, S. B., Contreras-Trujillo, H., Liu, J., Majeti, R., West, R. B., Fletcher, J. A., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121629109 · Cited by 258
Signal-Regulatory Protein Is Selectively Expressed by Myeloid and Neuronal Cells
Adams, S., van der Laan, L. J. W., Vernon-Wilson, E., Renardel de Lavalette, C., Döpp, E. A., Dijkstra, C. D., Simmons, D. L., & van den Berg, T. K. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.4.1853 · Cited by 258
Self-citationAnti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells
Kim, D., Wang, J., Willingham, S. B., Martin, R., Wernig, G., & Weissman, I. L. (2012) · Leukemia · doi:10.1038/leu.2012.141 · Cited by 249
CD47, a ligand for the macrophage fusion receptor, participates in macrophage multinucleation
Han, X., Sterling, H., Chen, Y., Saginario, C., Brown, E. J., Frazier, W. A., Lindberg, F. P., & Vignery, A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002334200 · Cited by 245
CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia
Mateo, V., Lagneaux, L., Bron, D., Biron, G., Armant, M., Delespesse, G., & Sarfati, M. (1999) · Nature Medicine · doi:10.1038/15233 · Cited by 241
Latour, S., Tanaka, H., Demeure, C., Mateo, V., Rubio, M., Brown, E. J., Maliszewski, C., Lindberg, F. P., Oldenborg, A., Ullrich, A., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.5.2547 · Cited by 238
Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms
Cioffi, M., Trabulo, S., Hidalgo, M., Costello, E., Greenhalf, W., Erkan, M., Kleeff, J., Sainz, B., & Heeschen, C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1399 · Cited by 229
Schneider-Merck, T., Lammerts van Bueren, J. J., Berger, S., Rossen, K., van Berkel, P. H. C., Derer, S., Beyer, T., Lohse, S., Bleeker, W. K., Peipp, M., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0900847 · Cited by 222
Signal Regulatory Protein (SIRPα), a Cellular Ligand for CD47, Regulates Neutrophil Transmigration
Liu, Y., Bühring, H.-J., Zen, K., Burst, S. L., Schnell, F. J., Williams, I. R., & Parkos, C. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109720200 · Cited by 217
Olsson, M., Bruhns, P., Frazier, W. A., Ravetch, J. V., & Oldenborg, P.-A. (2005) · Blood · doi:10.1182/blood-2004-08-2980 · Cited by 216
Hatherley, D., Graham, S. C., Turner, J., Harlos, K., Stuart, D. I., & Barclay, A. N. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.05.026 · Cited by 215
Lee, T. K.-W., Cheung, V. C.-H., Lu, P., Lau, E. Y. T., Ma, S., Tang, K. H., Tong, M., Lo, J., & Ng, I. O. L. (2014) · Hepatology · doi:10.1002/hep.27070 · Cited by 213
Signal Regulatory Proteins in the Immune System
van Beek, E. M., Cochrane, F., Barclay, A. N., & van den Berg, T. K. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.12.7781 · Cited by 204
Self-citationThe current spectrum of infection in cancer patients with chemotherapy related neutropenia
Nesher, L., & Rolston, K. V. I. (2014) · Infection · doi:10.1007/s15010-013-0525-9 · Cited by 202
Surfactant Proteins A and D Suppress Alveolar Macrophage Phagocytosis via Interaction with SIRPα
Janssen, W. J., McPhillips, K. A., Dickinson, M. G., Linderman, D. J., Morimoto, K., Xiao, Y. Q., Oldham, K. M., Vandivier, R. W., Henson, P. M., & Gardai, S. J. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200711-1661oc · Cited by 202
Gresham, H. D., Goodwin, J. L., Allen, P. M., Anderson, D. C., & Brown, E. J. (1989) · The Journal of cell biology · doi:10.1083/jcb.108.5.1935 · Cited by 201
Lo, J., Lau, E. Y. T., Ching, R. H. H., Cheng, B. Y. L., Ma, M. K. F., Ng, I. O. L., & Lee, T. K. W. (2015) · Hepatology · doi:10.1002/hep.27859 · Cited by 199
Chao, M. P., Tang, C., Pachynski, R. K., Chin, R., Majeti, R., & Weissman, I. L. (2011) · Blood · doi:10.1182/blood-2011-02-338020 · Cited by 194
The Role of CD47 in Neutrophil Transmigration
Liu, Y., Merlin, D., Burst, S. L., Pochet, M., Madara, J. L., & Parkos, C. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104138200 · Cited by 191
Wang, Y., Xu, Z., Guo, S., Zhang, L., Sharma, A., Robertson, G. P., & Huang, L. (2013) · Molecular Therapy · doi:10.1038/mt.2013.135 · Cited by 191
Hernandez‐Ilizaliturri, F. J., Jupudy, V., Ostberg, J. R., Oflazoglu, E., Huberman, A., Repasky, E. A., & Czuczman, M. S. (2003) · PubMed · Cited by 188
Seiffert, M., Brossart, P., Cant, C., Cella, M., Colonna, M., Brugger, W., Kanz, L., Ullrich, A., & Bühring, H.-J. (2001) · Blood · doi:10.1182/blood.v97.9.2741 · Cited by 183
CD47 is a ligand for rat macrophage membrane signal regulatory protein SIRP (OX41) and human SIRPα 1
Vernon-Wilson, E. F., Kee, W.-J., Willis, A. C., Barclay, A. N., Simmons, D. L., & Brown, M. H. (2000) · European Journal of Immunology · doi:10.1002/1521-4141(2000)30:18<2130::aid-immu2130>3.0.co;2-p · Cited by 176
CD47 signaling pathways controlling cellular differentiation and responses to stress
Soto-Pantoja, D. R., Kaur, S., & Roberts, D. D. (2015) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2015.1014024 · Cited by 173
Brooke, G., Holbrook, J. D., Brown, M. H., & Barclay, A. N. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.4.2562 · Cited by 171
CD47 Promotes Tumor Invasion and Metastasis in Non-small Cell Lung Cancer
Zhao, H., Wang, J., Kong, X., Li, E., Liu, Y., Du, X., Kang, Z., Tang, Y. C., Kuang, Y., Yang, Z., et al. (2016) · Scientific Reports · doi:10.1038/srep29719 · Cited by 168
Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma
Xiao, Z., Chung, H., Banan, B., Manning, P. T., Ott, K. C., Lin, S., Capoccia, B. J., Subramanian, V., Hiebsch, R. R., Upadhya, G. A., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.02.036 · Cited by 164
Ferreira, J. A., Peixoto, A., Neves, M., Gaiteiro, C., Reis, C. A., Assaraf, Y. G., & Santos, L. L. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2015.11.003 · Cited by 159
Janus-like opposing roles of CD47 in autoimmune brain inflammation in humans and mice
Han, M. H., Lundgren, D. H., Jaiswal, S., Chao, M., Graham, K. L., Garris, C. S., Axtell, R. C., Ho, P. P., Lock, C. B., Woodard, J. I., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20101974 · Cited by 157
Species- and cell type-specific interactions between CD47 and human SIRPα
Subramanian, S., Parthasarathy, R., Sen, S., Boder, E. T., & Discher, D. E. (2005) · Blood · doi:10.1182/blood-2005-04-1463 · Cited by 156
Neutrophils mediate antibody-induced antitumor effects in mice
Albanesi, M., Mancardi, D. A., Jönsson, F., Iannascoli, B., Fiette, L., Santo, J. P. D., Lowell, C. A., & Bruhns, P. (2013) · Blood · doi:10.1182/blood-2013-04-497446 · Cited by 154
Isenberg, J. S., Annis, D. S., Pendrak, M. L., Ptaszynska, M. M., Frazier, W. A., Mosher, D. F., & Roberts, D. D. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804860200 · Cited by 152
Piccione, E. C., Juárez, S., Liu, J., Tseng, S., Ryan, C. E., Narayanan, C., Wang, L., Weiskopf, K., & Majeti, R. (2015) · mAbs · doi:10.1080/19420862.2015.1062192 · Cited by 148
Yamao, T., Noguchi, T., Takeuchi, O., Nishiyama, U., Morita, H., Hagiwara, T., Akahori, H., Kato, T., Inagaki, K., Okazawa, H., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203287200 · Cited by 140
Campbell, I., Freemont, P. S., Foulkes, W. D., & Trowsdale, J. (1992) · PubMed · Cited by 140
Bian, Z., Shi, L., Guo, Y.-L., Lv, Z., Tang, C., Niu, S., Tremblay, A., Venkataramani, M., Culpepper, C. D., Li, L., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521069113 · Cited by 140
Theocharides, A. P. A., Jin, L., Cheng, P.-Y., Prasolava, T. K., Malko, A. V., Ho, J., Poeppl, A. G., van Rooijen, N., Minden, M. D., Danska, J. S., et al. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20120502 · Cited by 139
Kong, X., Yan, H., Chen, L., Dong, L., Yang, W., Liu, Q., Yu, L., Huang, D., Liu, S., Liu, H., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062611 · Cited by 138
DiLillo, D. J., & Ravetch, J. V. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0120 · Cited by 135
de Vries, H. E., Hendriks, J. J. A., Honing, H., de Lavalette, C. R., van der Pol, S. M. A., Hooijberg, E., Dijkstra, C. D., & van den Berg, T. K. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.11.5832 · Cited by 135
CD 47 is an adverse prognostic factor and a therapeutic target in gastric cancer
Yoshida, K., Tsujimoto, H., Matsumura, K., Kinoshita, M., Takahata, R., Matsumoto, Y., Hiraki, S., Ono, S., Seki, S., Yamamoto, J., et al. (2015) · Cancer Medicine · doi:10.1002/cam4.478 · Cited by 125
Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies
Münz, M., Murr, A., Kvesic, M., Rau, D., Mangold, S., Pflanz, S., Lumsden, J., Volkland, J., Fagerberg, J., Riethmüller, G., et al. (2010) · Cancer Cell International · doi:10.1186/1475-2867-10-44 · Cited by 125
Yi, T., Li, J., Chen, H., Wu, J., An, J., Xu, Y., Hu, Y., Lowell, C. A., & Cyster, J. G. (2015) · Immunity · doi:10.1016/j.immuni.2015.08.021 · Cited by 124
Ishikawa-Sekigami, T., Kaneko, Y., Okazawa, H., Tomizawa, T., Okajo, J., Saito, Y., Okuzawa, C., Sugawara-Yokoo, M., Nishiyama, U., Ohnishi, H., et al. (2005) · Blood · doi:10.1182/blood-2005-05-1896 · Cited by 119
Thrombospondin-1 Regulates Blood Flow via CD47 Receptor–Mediated Activation of NADPH Oxidase 1
Csányi, G., Yao, M., Rodriguez, A. I., Ghouleh, I. A., Sharifi‐Sanjani, M., Frazziano, G., Huang, X., Kelley, E. E., Isenberg, J. S., & Pagano, P. J. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.300031 · Cited by 112
Lethal autoimmune hemolytic anemia in CD47-deficient nonobese diabetic (NOD) mice
Oldenborg, P. (2002) · Blood · doi:10.1182/blood.v99.10.3500 · Cited by 108
Original insights on thrombospondin-1-related antireceptor strategies in cancer
Jeanne, A., Schneider, C., Martiny, L., & Dedieu, S. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00252 · Cited by 108
Kaur, S., ELKAHLOUN, A. G., SINGH, S. P., Chen, Q., Meerzaman, D. M., Song, T., Manu, N., Wu, W., Mannan, P., Garfield, S. H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7100 · Cited by 107
Evolution of the Ly49 and Nkrp1 recognition systems
Carlyle, J. R., Mesci, A., Fine, J. H., Chen, P., Bélanger, S., Tai, L., & Makrigiannis, A. P. (2008) · Seminars in Immunology · doi:10.1016/j.smim.2008.05.004 · Cited by 105
Role of CD47 in Erythroid Cells and in Autoimmunity
Oldenborg, P. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/1042819042000201989 · Cited by 103
AMPKα1 Deletion Shortens Erythrocyte Life Span in Mice
Wang, S., Dale, G. L., Song, P., Viollet, B., & Zou, M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.102467 · Cited by 100
SUZUKI, S., YOKOBORI, T., TANAKA, N., SAKAI, M., SANO, A., INOSE, T., SOHDA, M., NAKAJIMA, M., MIYAZAKI, T., KATO, H., et al. (2012) · Oncology Reports · doi:10.3892/or.2012.1831 · Cited by 100
Stefanidakis, M., Newton, G. A., Lee, W. Y., Parkos, C. A., & Luscinskas, F. W. (2008) · Blood · doi:10.1182/blood-2008-01-134429 · Cited by 99
Kwong, L. S., Brown, M. H., Barclay, A. N., & Hatherley, D. (2014) · Immunology · doi:10.1111/imm.12290 · Cited by 96
Lack of CD47 on nonhematopoietic cells induces split macrophage tolerance to CD47 null cells
Wang, H., Madariaga, M. L. L., Wang, S., van Rooijen, N., Oldenborg, P., & Yang, Y. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702881104 · Cited by 94
Ho, C. C. M., Ring, N. G., Sockolosky, J. T., Ring, A. M., Weiskopf, K., Özkan, E., Mori, Y., Weissman, I. L., & García, K. C. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.648220 · Cited by 93
On the origins of adaptive immunity: innate immune receptors join the tale
VandenBerg, T., Yoder, J. A., & Litman, G. W. (2003) · Trends in Immunology · doi:10.1016/j.it.2003.11.006 · Cited by 93
Self-citationIdentification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine tumors
Krampitz, G. W., George, B. M., Willingham, S. B., Volkmer, J.-P., Weiskopf, K., Jahchan, N. S., Newman, A. M., Sahoo, D., Zemek, A., Yanovsky, R. L., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600007113 · Cited by 89
CD47 blockade inhibits tumor progression human osteosarcoma in xenograft models
Xu, J.-F., Pan, X.-H., Zhang, S.-J., Zhao, C., Qiu, B.-S., Gu, H.-F., Hong, J.-F., Cao, L., Chen, Y., Xia, B., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4282 · Cited by 88
The CD47 “don't eat me signal” is highly expressed in human ovarian cancer
Brightwell, R. M., Grzankowski, K. S., Lele, S., Eng, K. H., Arshad, M., Chen, H., & Odunsi, K. O. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.08.325 · Cited by 86
A role for CD47 in the development of experimental colitis mediated by SIRPα+CD103− dendritic cells
Fortin, G., Raymond, M., Van, V. Q., Rubio, M., Gautier, P., Sarfati, M., & Franchimont, D. P. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20082805 · Cited by 85
Martínez‐Torres, A. C., Quiney, C., Attout, T., Boullet, H., Herbi, L., Vela, L., Barbier, S., Château, D., Chapiro, É., Nguyen‐Khac, F., et al. (2015) · PLoS Medicine · doi:10.1371/journal.pmed.1001796 · Cited by 85
Raymond, M., Rubio, M., Fortin, G., Shalaby, K. H., Hammad, H., Lambrecht, B. N., & Sarfati, M. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.07.021 · Cited by 84
Immune Checkpoint Inhibitors Side Effects and Management
Kourié, H. R., & Klastersky, J. A. (2016) · Immunotherapy · doi:10.2217/imt-2016-0029 · Cited by 84
Alblas, J., Honing, H., de Lavalette, C. R., Brown, M. H., Dijkstra, C. D., & van den Berg, T. K. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.16.7181-7192.2005 · Cited by 82
CD47 in the Immune Response: Role of Thrombospondin and SIRP-α Reverse Signaling
Sarfati, M., Fortin, G., Raymond, M., & Susín, S. A. (2008) · Current Drug Targets · doi:10.2174/138945008785909310 · Cited by 81
Positive Regulation of Phagocytosis by SIRPβ and Its Signaling Mechanism in Macrophages
Hayashi, A., Ohnishi, H., Okazawa, H., Nakazawa, S., Ikeda, H., Motegi, S., Aoki, N., Kimura, S., Mikuni, M., & Matozaki, T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400950200 · Cited by 81
Siders, W., Shields, J. D., Garron, C., Hu, Y., Boutin, P., Shankara, S., Weber, W. D., Roberts, B., & Kaplan, J. M. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428191003777963 · Cited by 77
Regulation by SIRPα of dendritic cell homeostasis in lymphoid tissues
Saito, Y., Iwamura, H., Kaneko, T., Ohnishi, H., Murata, Y., Okazawa, H., Kanazawa, Y., Sato‐Hashimoto, M., Kobayashi, H., Oldenborg, P., et al. (2010) · Blood · doi:10.1182/blood-2010-03-277244 · Cited by 74
Kuriyama, T., Takenaka, K., Kohno, K., Yamauchi, T., Daitoku, S., Yoshimoto, G., Kikushige, Y., Kishimoto, J., Abe, Y., Harada, N., et al. (2012) · Blood · doi:10.1182/blood-2012-02-408864 · Cited by 70
Cleavage of Signal Regulatory Protein α (SIRPα) Enhances Inflammatory Signaling
Londino, J. D., Gulick, D. L., Isenberg, J. S., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.682914 · Cited by 59
Zen, K., Guo, Y., Bian, Z., Lv, Z., Zhu, D., Ohnishi, H., Matozaki, T., & Liu, Y. (2013) · Nature Communications · doi:10.1038/ncomms3436 · Cited by 55
Tomizawa, T., Kaneko, Y., Kaneko, Y., Saito, Y., Ohnishi, H., Okajo, J., Okuzawa, C., Ishikawa-Sekigami, T., Murata, Y., Okazawa, H., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.2.869 · Cited by 52
Goto, H., Kojima, Y., Matsuda, K., Kariya, R., Taura, M., Kuwahara, K., Nagai, H., Katano, H., & Okada, S. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.03.004 · Cited by 51
Hatherley, D., Lea, S. M., Johnson, S., & Barclay, A. N. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.550558 · Cited by 51
SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells
Piccione, E. C., Juárez, S., Tseng, S., Liu, J., Stafford, M., Narayanan, C., Wang, L., Weiskopf, K., & Majeti, R. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2503 · Cited by 51
Yang, S. Y., Choi, S. A., Lee, J. Y., Park, A.-K., Wang, K., Phi, J. H., Koh, E. J., Park, W., Park, S., Hwang, D. W., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6227 · Cited by 50
Ayi, K., Lu, Z., Serghides, L., Ho, J., Finney, C. A. M., Wang, J. C. Y., Liles, W. C., & Kain, K. C. (2016) · Infection and Immunity · doi:10.1128/iai.01426-15 · Cited by 49
CD47 deficiency in tumor stroma promotes tumor progression by enhancing angiogenesis
Gao, L., Chen, K., Gao, Q., Wang, X., Sun, J., & Yang, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.9899 · Cited by 47
Divergent modulation of normal and neoplastic stem cells by thrombospondin-1 and CD47 signaling
Kaur, S., & Roberts, D. D. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.05.005 · Cited by 45
Enhanced phagocytosis of CD47-deficient red blood cells by splenic macrophages requires SHPS-1
Ishikawa-Sekigami, T., Kaneko, Y., Saito, Y., Murata, Y., Okazawa, H., Ohnishi, H., Oldenborg, P., Nojima, Y., & Matozaki, T. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.03.094 · Cited by 42
Inhibition of SIRPα in dendritic cells potentiates potent antitumor immunity
Liu, Q., Wen, W., Tang, L., Qin, C., Lin, Y., Zhang, H., Wu, H., Ashton, C., Wu, H., Ding, J., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1183850 · Cited by 41
Wong, A. S. L., Mortin-Toth, S. M., Sung, M., Canty, A. J., Gulban, O., Greaves, D. R., & Danska, J. S. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401984 · Cited by 35
On the mechanism of CD47 targeting in cancer
Zhao, X. W., Matlung, H. L., Kuijpers, T. W., & van den Berg, T. K. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209265109 · Cited by 35
Self-citationCD47 Promotes Protective Innate and Adaptive Immunity in a Mouse Model of Disseminated Candidiasis
Navarathna, D. H. M. L. P., Stein, E. V., Lessey-Morillon, E. C., Nayak, D., Martin‐Manso, G., & Roberts, D. D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128220 · Cited by 33
SIRPα Controls the Activity of the Phagocyte NADPH Oxidase by Restricting the Expression of gp91phox
van Beek, E. M., Zárate, J. Á., van Bruggen, R., Schornagel, K., Tool, A. T. J., Matozaki, T., Kraal, G., Roos, D., & van den Berg, T. K. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.08.027 · Cited by 32
Is targeting of CD47-SIRPα enough for treating hematopoietic malignancy?
Zhao, X. W., Kuijpers, T. W., & van den Berg, T. K. (2012) · Blood · doi:10.1182/blood-2011-11-391367 · Cited by 32
Wang, Y., Yin, C., Feng, L., Wang, C., & Sheng, G. (2015) · Genetics and Molecular Research · doi:10.4238/2015.may.25.15 · Cited by 31
Mishima, Y., Terui, Y., Mishima, Y. M., Kuniyoshi, R., Matsusaka, S., Mikuniya, M., Kojima, K., & Hatake, K. (2012) · International Immunology · doi:10.1093/intimm/dxs048 · Cited by 30
Fournier, B., Andargachew, R., Robin, A. Z., Laur, O., Voelker, D. R., Lee, W. Y., Weber, D. A., & Parkos, C. A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.324533 · Cited by 28
Soto‐Pantoja, D. R., Miller, T. W., Frazier, W. A., & Roberts, D. D. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205441109 · Cited by 25
Resistance to collagen-induced arthritis in SHPS-1 mutant mice
Okuzawa, C., Kaneko, Y., Murata, Y., Miyake, A., Saito, Y., Okajo, J., Tomizawa, T., Kaneko, Y., Okazawa, H., Ohnishi, H., et al. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.04.124 · Cited by 25
CD47high Expression on CD4 Effectors Identifies Functional Long-Lived Memory T Cell Progenitors
Van, V. Q., Raymond, M., Baba, N., Rubio, M., Wakahara, K., Susín, S. A., & Sarfati, M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102702 · Cited by 25
Irandoust, M. I., Zárate, J. Á., Hubeek, I., van Beek, E. M., Schornagel, K., Broekhuizen, A. J. F., Akyuz, M., van de Loosdrecht, A. A., Delwel, R., Valk, P. J. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0052143 · Cited by 20
Bian, Z., Guo, Y.-L., Luo, Y., Tremblay, A., Zhang, X., Dharma, S. S., Mishra, A., & Liu, Y. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201963 · Cited by 19
Targeting SIRP‐α protects from type 2‐driven allergic airway inflammation
Raymond, M., Van, V. Q., Rubio, M., Welzenbach, K., & Sarfati, M. (2010) · European Journal of Immunology · doi:10.1002/eji.201040797 · Cited by 18
Shi, L., Bian, Z., Chen, C. X.-J., Guo, Y., Lv, Z., Zeng, C., Liu, Z., Zen, K., & Liu, Y. (2015) · The Journal of Pathology · doi:10.1002/path.4574 · Cited by 18
Regulation of Phagocyte Migration by Signal Regulatory Protein-Alpha Signaling
Zárate, J. Á., Matlung, H. L., Matozaki, T., Kuijpers, T. W., Maridonneau‐Parini, I., & van den Berg, T. K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127178 · Cited by 15
Self-citationIncreased Susceptibility to Salmonella Infection in Signal Regulatory Protein α-Deficient Mice
Li, L., Atif, S. M., Schmiel, S. E., Lee, S., & McSorley, S. J. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200429 · Cited by 12
Baral, P., & Utaisincharoen, P. (2013) · Infection and Immunity · doi:10.1128/iai.00519-13 · Cited by 12
Upregulation of CD47 in Regulatory T Cells in Atopic Dermatitis
Lee, N., Shin, J. U., Jin, S., Yun, K. N., Kim, J. Y., Park, C. O., Kim, S. H., Noh, J. Y., & Lee, K. H. (2016) · Yonsei Medical Journal · doi:10.3349/ymj.2016.57.6.1435 · Cited by 10
Pinessi, D., Foglieni, C., Bugatti, A., Moroni, E., Resovi, A., Ribatti, D., Rusnati, M., Giavazzi, R., Colombo, G., & Taraboletti, G. (2016) · Thrombosis Research · doi:10.1016/s0049-3848(16)30148-7 · Cited by 8
Reply to Soto-Pantoja et al. and Zhao et al.: Targeting CD47 on human solid tumors
Willingham, S. B., Volkmer, J.-P., Weiskopf, K., Ring, A. M., & Weissman, I. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209743109 · Cited by 5
Requirement of SIRPα for protective immunity against Leishmania major
Morimoto, N., Murata, Y., Motegi, S., Suzue, K., Saito, Y., Okazawa, H., Ohnishi, H., Kotani, T., Kusakari, S., Ishikawa, O., et al. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.09.062 · Cited by 5
Response: mechanisms of targeting CD47-SIRPα in hematologic malignancies
Chao, M. P., Majeti, R., & Weissman, I. L. (2012) · Blood · doi:10.1182/blood-2012-02-411249 · Cited by 4
Immune checkpoint blockade: Which switches to hit and how much?
Matlung, H. L., Szilagyi, K., Kuijpers, T. W., van Lier, R. A. W., & van den Berg, T. K. (2016) · Immunology Letters · doi:10.1016/j.imlet.2016.08.014 · Cited by 1
Self-citation
Cited by
Therapeutic Targeting of the Tumor Microenvironment
Bejarano, L., Jordāo, M. J. C., & Joyce, J. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1808 · Cited by 1,653
Tumour-associated neutrophils in patients with cancer
Shaul, M. E., & Fridlender, Z. G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0222-4 · Cited by 1,023
Engineering Macrophages for Cancer Immunotherapy and Drug Delivery
Xia, Y., Rao, L., Yao, H., Wang, Z., Ning, P., & Chen, X. (2020) · Advanced Materials · doi:10.1002/adma.202002054 · Cited by 949
The complex role of tumor-infiltrating macrophages
Christofides, A., Strauss, L., Yeo, A., Cao, C., Charest, A., & Boussiotis, V. A. (2022) · Nature Immunology · doi:10.1038/s41590-022-01267-2 · Cited by 849
m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade
Yang, S., Wei, J., Cui, Y.-H., Park, G., Shah, P., Deng, Y., Aplin, A. E., Lu, Z., Hwang, S., He, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10669-0 · Cited by 743
Metadata
- Authors
- Matlung, H. L., Szilagyi, K., Barclay, N. A., & van den Berg, T. K.
- Venue
- Immunological Reviews
- Publisher
- Wiley
- Published
- 2017-03
- Volume
- 276
- Issue
- 1
- Pages
- 145-164
- ISSN
- 0105-2896 (ISSN-L)
- 1600-065X
- OpenAlex
- W2594014934
- Cited by
- 557
- References
- 160
- FWCI
- 3.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.